Sign In

Graham Doyle

Head of European MedTech, Equity Research at UBS

Graham Doyle

Graham Doyle is an Executive Director and Head of European MedTech in the Equity Research department at UBS in London.13 He has over 10 years of experience as a healthcare equity research analyst covering European pharmaceutical, medical technology, and healthcare services companies.1

Professional Experience

  • Executive Director, Equity Research at UBS (October 2021 - Present)1
  • Healthcare Equity Research Analyst at Liberum (September 2016 - October 2021)1
  • Healthcare Equity Research Analyst at Berenberg (July 2013 - September 2016)1
  • Healthcare Equity Research Analyst at Liberum (August 2011 - July 2013)1

Education

  • Bachelor of Arts (B.A.), Economics, 1.1 from Trinity College, Dublin (2007 - 2011)1

Stock Coverage and Performance

As an analyst at UBS, Graham Doyle currently covers 16 stocks across the healthcare sector with a 51% success rate and an average return of -6.6%.3 Some of his recent notable ratings include:

  • Alcon (ALC): Buy rating with a $102.68 price target (July 2024)4
  • Koninklijke Philips (PHG): Neutral rating (April 2024)2
  • GE HealthCare Technologies (GEHC): Neutral rating with an $88 price target (February 2024)2

Highlights

Apr 28 · linkedin

Thanks Keith Byrne. For the appreciation of healthcare staff and front line workers who wear masks that leave marks #markforheroes I show my appreciation by donating to NHS Charities and spread the pledge by calling on Euan Brown, Shane De Bhrun-Smith and Fintan Ryan, CFA to spread it too!

Related Questions

What are Graham Doyle's most notable achievements in his career?
How does Graham Doyle's success rate compare to other analysts at UBS?
What specific companies does Graham Doyle cover in the MedTech sector?
How has Graham Doyle's performance impacted UBS's investment strategies?
What is Graham Doyle's educational background and how has it influenced his career?
Graham Doyle
Add to my network

Location

London, England, United Kingdom